col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Springer Science and Business Media LLC: Signal Transduction and Targeted Therapy
  original article Date Title Authors   All Authors
1 [GO] 2022―Jan―19 The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain Jiajing Wu, Jianhui Nie, Li Zhang, Hao Song, Yimeng An, Ziteng Liang, et al. (+13)
2 [GO] 2022―Jan―11 A binding-enhanced but enzymatic activity-eliminated human ACE2 efficiently neutralizes SARS-CoV-2 variants Anqi Zheng, Lili Wu, Renyi Ma, Pu Han, Baoying Huang, Chengpeng Qiao, et al. (+4)
3 [GO] 2022―Jan―05 SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2 Leyun Wu, Liping Zhou, Mengxia Mo, Tingting Liu, Chengkun Wu, Chunye Gong, et al. (+4)
4 [GO] 2022―Jan―04 USP10 regulates B cell response to SARS-CoV-2 or HIV-1 nanoparticle vaccines through deubiquitinating AID Yuewen Luo, Xiantao Zhang, Ran Chen, Rong Li, Yang Liu, Junsong Zhang, et al. (+12)
5 [GO] 2021―Dec―24 Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates Hui Zhao, Tie-Cheng Wang, Xiao-Feng Li, Na-Na Zhang, Liang Li, Chao Zhou, et al. (+20)
6 [GO] 2021―Dec―24 Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human ACE2-transgenic mice Zhenfei Bi, Weiqi Hong, Haiying Que, Cai He, Wenyan Ren, Jingyun Yang, et al. (+5)
7 [GO] 2021―Dec―21 Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry Shulong Zu, Dan Luo, Lili Li, Qing Ye, Rui-Ting Li, Yanan Wang, et al. (+4)
8 [GO] 2021―Dec―17 Escaping alveolar macrophage endosomal retention explains massive expansion of SARS-CoV-2 delta variant Zhenfeng Wang, Yabo Zhou, Linlin Bao, Dan Li, Jiadi Lv, Dianheng Wang, et al. (+5)
9 [GO] 2021―Dec―17 SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance Xiantao Zhang, Shijian Wu, Bolin Wu, Qirui Yang, Achun Chen, Yuzhuang Li, et al. (+4)
10 [GO] 2021―Dec―17 SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury Meng-Li Wu, Feng-Liang Liu, Jing Sun, Xin Li, Xiao-Yan He, Hong-Yi Zheng, et al. (+10)
11 [GO] 2021―Dec―16 COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors Xi He, Chenshu Liu, Jiangyun Peng, Zilun Li, Fang Li, Jian Wang, et al. (+43)
12 [GO] 2021―Dec―14 Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route Ting Pan, Ran Chen, Xin He, Yaochang Yuan, Xiaohui Deng, Rong Li, et al. (+10)
13 [GO] 2021―Dec―14 Heterologous prime-boost with AdC68- and mRNA-based COVID-19 vaccines elicit potent immune responses in mice Wenjuan Li, Xingxing Li, Danhua Zhao, Jingjing Liu, Ling Wang, Miao Li, et al. (+4)
14 [GO] 2021―Dec―10 Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks Louisa Ruhl, Isabell Pink, Jenny F. Kühne, Kerstin Beushausen, Jana Keil, Stella Christoph, et al. (+11)
15 [GO] 2021―Dec―06 Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients Jin-Lan Zhang, Yu-Huan Li, Lu-Lu Wang, Hong-Qi Liu, Shuai-Yao Lu, Yong Liu, et al. (+23)
16 [GO] 2021―Dec―02 A novel model of molnupiravir against SARS-CoV-2 replication: accumulated RNA mutations to induce error catastrophe Yuxi Zhao, Gu He, Wei Huang
17 [GO] 2021―Nov―23 Neurological complications and infection mechanism of SARS-COV-2 Dandan Wan, Tingfu Du, Weiqi Hong, Li Chen, Haiying Que, Shuaiyao Lu, Xiaozhong Peng
18 [GO] 2021―Nov―15 The glycosylation in SARS-CoV-2 and its receptor ACE2 Yanqiu Gong, Suideng Qin, Lunzhi Dai, Zhixin Tian
19 [GO] 2021―Nov―10 RBD206-sc-dimer induced robust cross-neutralization against SARS-CoV-2 and variants of concern Chuge Zhou, Xiaodong Zai, Ziqing Zhou, Ruihua Li, Yue Zhang, Yaohui Li, et al. (+4)
20 [GO] 2021―Nov―10 Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein Hongyue Li, Yuhang Zhang, Dong Li, Yong-Qiang Deng, Hongde Xu, Chaoyue Zhao, et al. (+12)
21 [GO] 2021―Nov―09 The way of SARS-CoV-2 vaccine development: success and challenges Yetian Dong, Tong Dai, Bin Wang, Lei Zhang, Ling-hui Zeng, Jun Huang, et al. (+3)
22 [GO] 2021―Nov―03 A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants Zhenlin Yang, Yulu Wang, Yujia Jin, Yuanfei Zhu, Yanling Wu, Cheng Li, et al. (+20)
23 [GO] 2021―Nov―03 Sensing of cytoplasmic chromatin by cGAS activates innate immune response in SARS-CoV-2 infection Zhuo Zhou, Xinyi Zhang, Xiaobo Lei, Xia Xiao, Tao Jiao, Ruiyi Ma, et al. (+13)
24 [GO] 2021―Oct―27 Myeloid cells in COVID-19 microenvironment Guohui Qin, Shasha Liu, Li Yang, Weina Yu, Yi Zhang
25 [GO] 2021―Oct―26 Attenuating innate immunity and facilitating β-coronavirus infection by NSP1 of SARS-CoV-2 through specific redistributing hnRNP A2/B1 cellular localization Fanghang Zhou, Qianya Wan, Sheng Chen, Ying Chen, Pui-Hui Wang, Xi Yao, Ming-liang He
26 [GO] 2021―Oct―25 Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice Jia-Qi Li, Zhe-Rui Zhang, Hong-Qing Zhang, Ya-Nan Zhang, Xiang-Yue Zeng, Qiu-Yan Zhang, et al. (+4)
27 [GO] 2021―Oct―13 SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection Yan Zhan, Yufang Zhu, Shanshan Wang, Shijun Jia, Yunling Gao, Yingying Lu, et al. (+19)
28 [GO] 2021―Oct―12 Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients Yuanling Yu, Meiyu Wang, Xiaoai Zhang, Shufen Li, Qingbin Lu, Haolong Zeng, et al. (+20)
29 [GO] 2021―Sep―29 High-throughput screening and evaluation of repurposed drugs targeting the SARS-CoV-2 main protease Yan Li, Jinyong Zhang, Zilei Duan, Ning Wang, Xiangcheng Sun, Yanjing Zhang, et al. (+9)
30 [GO] 2021―Sep―27 SARS-CoV-2 Variants of Concern Delta: a great challenge to prevention and control of COVID-19 Maochen Li, Fuxing Lou, Huahao Fan
31 [GO] 2021―Sep―25 CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma Jiejie Geng, Liang Chen, Yufeng Yuan, Ke Wang, Youchun Wang, Chuan Qin, et al. (+42)
32 [GO] 2021―Sep―22 SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism Yukai Jing, Li Luo, Ying Chen, Lisa S. Westerberg, Peng Zhou, Zhiping Xu, et al. (+12)
33 [GO] 2021―Sep―20 Human genetic basis of coronavirus disease 2019 Hao Deng, Xue Yan, Lamei Yuan
34 [GO] 2021―Sep―16 Single-cell immune profiling reveals distinct immune response in asymptomatic COVID-19 patients Xiang-Na Zhao, Yue You, Xiao-Ming Cui, Hui-Xia Gao, Guo-Lin Wang, Sheng-Bo Zhang, et al. (+12)
35 [GO] 2021―Sep―16 S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis Fei Ye, Xi Lin, Zimin Chen, Fanli Yang, Sheng Lin, Jing Yang, et al. (+15)
36 [GO] 2021―Sep―09 The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice Wenqiang Sun, Lihong He, He Zhang, Xiaodong Tian, Zhihua Bai, Lei Sun, et al. (+8)
37 [GO] 2021―Sep―08 Mesenchymal stem cell therapy for severe COVID-19 Lei Shi, Lifeng Wang, Ruonan Xu, Chao Zhang, Yunbo Xie, Kai Liu, et al. (+4)
38 [GO] 2021―Sep―06 SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration Ling Zhang, Li Zhou, Linlin Bao, Jiangning Liu, Hua Zhu, Qi Lv, et al. (+15)
39 [GO] 2021―Sep―06 SARS-CoV-2 leads to myocardial injury in rhesus macaque Yufan Feng, Xiaomin Song, Yongfa Huang, Wei Deng, Man Li, Xiaoxiao Guo, et al. (+4)
40 [GO] 2021―Sep―01 Pro-inflammatory microenvironment and systemic accumulation of CXCR3+ cell exacerbate lung pathology of old rhesus macaques infected with SARS-CoV-2 Hong-Yi Zheng, Xiao-Yan He, Wei Li, Tian-Zhang Song, Jian-Bao Han, Xiang Yang, et al. (+8)
41 [GO] 2021―Sep―01 A dual-role of SARS-CoV-2 nucleocapsid protein in regulating innate immune response Yinghua Zhao, Liyan Sui, Ping Wu, Wenfang Wang, Zedong Wang, Yang Yu, et al. (+4)
42 [GO] 2021―Aug―31 Correction: The signal pathways and treatment of cytokine storm in COVID-19 Lan Yang, Xueru Xie, Zikun Tu, Jinrong Fu, Damo Xu, Yufeng Zhou
43 [GO] 2021―Aug―26 Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies Yu-Wen Zhou, Yao Xie, Lian-Sha Tang, Dan Pu, Ya-Juan Zhu, Ji-Yan Liu, Xue-Lei Ma
44 [GO] 2021―Aug―25 Applications of laboratory findings in the prevention, diagnosis, treatment, and monitoring of COVID-19 Zirui Meng, Shuo Guo, Yanbing Zhou, Mengjiao Li, Minjin Wang, Binwu Ying
45 [GO] 2021―Aug―25 ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker Yuning Chen, Ya-Nan Zhang, Renhong Yan, Guifeng Wang, Yuanyuan Zhang, Zhe-Rui Zhang, et al. (+11)
46 [GO] 2021―Aug―18 HIF-1α promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19 Mingfu Tian, Weiyong Liu, Xiang Li, Peiyi Zhao, Muhammad Adnan Shereen, Chengliang Zhu, et al. (+12)
47 [GO] 2021―Aug―17 Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients Linlin Cheng, Xiaomei Zhang, Yu Chen, Dan Wang, Dong Zhang, Songxin Yan, et al. (+24)
48 [GO] 2021―Aug―17 “Armed for the future Coronavirus pandemic”: a promising use of the multimeric SARS-CoV-2 receptor binding domain nanoparticle as a new Pan-Coronavirus vaccine Manoj Kumar, Souhaila Al Khodor
49 [GO] 2021―Aug―13 SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses Yuanmei Zhu, Danwei Yu, Yue Hu, Tong Wu, Huihui Chong, Yuxian He
50 [GO] 2021―Aug―11 Decreased inhibition of exosomal miRNAs on SARS-CoV-2 replication underlies poor outcomes in elderly people and diabetic patients Yanbo Wang, Xiaoju Zhu, Xia-Ming Jiang, Jingwei Guo, Zheng Fu, Zhen Zhou, et al. (+11)
51 [GO] 2021―Jul―30 Correction: SARS-CoV-2-specific immune response in COVID-19 convalescent individuals Yunbao Pan, Xianghu Jiang, Liu Yang, Liangjun Chen, Xiaojiao Zeng, Guohong Liu, et al. (+7)
52 [GO] 2021―Jul―30 Multimodal single-cell omics analysis identifies epithelium-immune cell interactions and immune vulnerability associated with sex differences in COVID-19 Yuan Hou, Yadi Zhou, Michaela U. Gack, Justin D. Lathia, Asha Kallianpur, Reena Mehra, et al. (+5)
53 [GO] 2021―Jul―29 Differential immune responses in pregnant patients recovered from COVID-19 Ge Chen, Yiming Zhang, Yaoyao Zhang, Jihui Ai, Bin Yang, Mengge Cui, et al. (+13)
54 [GO] 2021―Jul―29 Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation Shuai Xia, Qiaoshuai Lan, Yun Zhu, Chao Wang, Wei Xu, Yutang Li, et al. (+17)
55 [GO] 2021―Jul―27 Assessment of infectivity and the impact on neutralizing activity of immune sera of the COVID-19 variant, CAL.20C Zhongcheng Zhou, Peng Du, Meixing Yu, Daniel T. Baptista-Hon, Man Miao, Andy P. Xiang, et al. (+10)
56 [GO] 2021―Jul―27 N501Y mutation imparts cross-species transmission of SARS-CoV-2 to mice by enhancing receptor binding Zubiao Niu, Zhengrong Zhang, Xiaoyan Gao, Peng Du, Jingjing Lu, Bohua Yan, et al. (+4)
57 [GO] 2021―Jul―17 A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus Junzhi Wang
58 [GO] 2021―Jul―15 Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials Fan-Yue Meng, Fan Gao, Si-Yue Jia, Xiang-Hong Wu, Jing-Xin Li, Xi-Ling Guo, et al. (+13)
59 [GO] 2021―Jul―14 Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients Cameron Mura, Saskia Preissner, Susanne Nahles, Max Heiland, Philip E. Bourne, Robert Preissner
60 [GO] 2021―Jul―12 The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction Suowen Xu, Yujie Liu, Yu Ding, Sihui Luo, Xueying Zheng, Xiumei Wu, et al. (+7)
61 [GO] 2021―Jul―07 The signal pathways and treatment of cytokine storm in COVID-19 Lan Yang, Xueru Xie, Zikun Tu, Jinrong Fu, Damo Xu, Yufeng Zhou
62 [GO] 2021―Jul―07 SARS-CoV-2-specific immune response in COVID-19 convalescent individuals Yunbao Pan, Xianghu Jiang, Liu Yang, Liangjun Chen, Xiaojiao Zeng, Guohong Liu, et al. (+7)
63 [GO] 2021―Jul―07 Catch-as-catch-can: mRNA vaccination boosts immune responses to SARS-CoV-2 variants Graham Pawelec, Emilie Picard
64 [GO] 2021―Jun―11 Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy Qianqian Zhang, Rong Xiang, Shanshan Huo, Yunjiao Zhou, Shibo Jiang, Qiao Wang, Fei Yu
65 [GO] 2021―Jun―11 Palmitoylation of SARS-CoV-2 S protein is essential for viral infectivity Zhuanchang Wu, Zhaoying Zhang, Xin Wang, Jing Zhang, Caiyue Ren, Yuming Li, et al. (+4)
66 [GO] 2021―Jun―10 Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction ChangDong Lin, Yue Li, YueBin Zhang, ZhaoYuan Liu, Xia Mu, Chenjian Gu, et al. (+4)
67 [GO] 2021―Jun―10 Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1 Ge Yang, Ziyue Li, Irfan Mohammed, Liping Zhao, Wei Wei, Haihua Xiao, et al. (+4)
68 [GO] 2021―Jun―09 Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines Weilin Zhou, Wei Wang
69 [GO] 2021―Jun―07 Coagulation factors and the incidence of COVID-19 severity: Mendelian randomization analyses and supporting evidence Yao Zhou, Xinyi Qian, Zipeng Liu, Hongxi Yang, Tong Liu, Kexin Chen, et al. (+4)
70 [GO] 2021―Jun―03 Sera proteomic features of active and recovered COVID-19 patients: potential diagnostic and prognostic biomarkers Ling Leng, Mansheng Li, Wei Li, Danlei Mou, Guopeng Liu, Jie Ma, et al. (+4)
71 [GO] 2021―Jun―01 Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 Mpro Zhengyuan Wang, Yao Zhao, Qingxing Wang, Yangfei Xing, Lu Feng, Juan Kong, et al. (+4)
72 [GO] 2021―May―31 A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity Ren Yang, Yao Deng, Baoying Huang, Lei Huang, Ang Lin, Yuhua Li, et al. (+20)
73 [GO] 2021―May―29 Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease Qi Sun, Fei Ye, Hao Liang, Hongbo Liu, Chunmei Li, Roujian Lu, et al. (+4)
74 [GO] 2021―May―22 SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern Ji Yun Noh, Hye Won Jeong, Eui-Cheol Shin
75 [GO] 2021―May―22 SARS-CoV-2 nanobodies 2.0 Fabien Labroussaa, Joerg Jores
76 [GO] 2021―May―20 Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza Linlin Bao, Wei Deng, Feifei Qi, Qi Lv, Zhiqi Song, Jiangning Liu, et al. (+14)
77 [GO] 2021―May―18 COVID-19 vaccines: progress and understanding on quality control and evaluation Qunying Mao, Miao Xu, Qian He, Changgui Li, Shufang Meng, Yiping Wang, et al. (+3)
78 [GO] 2021―May―18 Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study Xin Xu, Sheng Nie, Yanqun Wang, Quanxin Long, Hong Zhu, Xiaoyong Zhang, et al. (+8)
79 [GO] 2021―May―18 Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction ChangDong Lin, Yue Li, YueBin Zhang, ZhaoYuan Liu, Xia Mu, Chenjian Gu, et al. (+4)
80 [GO] 2021―May―17 Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq Bing He, Shuning Liu, Yuanyuan Wang, Mengxin Xu, Wei Cai, Jia Liu, et al. (+22)
81 [GO] 2021―May―17 Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial Huijie Bian, Zhao-Hui Zheng, Ding Wei, Aidong Wen, Zheng Zhang, Jian-Qi Lian, et al. (+52)
82 [GO] 2021―May―17 Cellular tropism and antigenicity of mink-derived SARS-CoV-2 variants Li Zhang, Qianqian Li, Jianhui Nie, Ruxia Ding, Haixin Wang, Jiajing Wu, et al. (+4)
83 [GO] 2021―May―13 Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19 Shengli Ma, Fan Zhang, Fengxia Zhou, Hui Li, Wenyu Ge, Rui Gan, et al. (+9)
84 [GO] 2021―May―13 Correction: A systemic and molecular study of subcellular localization of SARS-CoV-2 proteins Jing Zhang, Ruth Cruz-cosme, Meng-Wei Zhuang, Dongxiao Liu, Yuan Liu, Shaolei Teng, et al. (+2)
85 [GO] 2021―May―12 The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry Junsong Zhang, Feng Huang, Baijin Xia, Yaochang Yuan, Fei Yu, Guanwen Wang, et al. (+9)
86 [GO] 2021―May―10 Viral dynamics and antibody responses in people with asymptomatic SARS-CoV-2 infection Zhiwei Sui, Xinhua Dai, Qingbin Lu, Yulan Zhang, Min Huang, Shufen Li, et al. (+17)
87 [GO] 2021―May―10 Lenalidomide downregulates ACE2 protein abundance to alleviate infection by SARS-CoV-2 spike protein conditioned pseudoviruses Siyuan Su, Jianfeng Chen, Ying Wang, Lilly M. Wong, Zhichuan Zhu, Guochun Jiang, Pengda Liu
88 [GO] 2021―May―08 SARS-CoV-2 promote autophagy to suppress type I interferon response Xianfeng Hui, Linliang Zhang, Lei Cao, Kun Huang, Ya Zhao, Yufei Zhang, et al. (+4)
89 [GO] 2021―Apr―24 An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19 Yiyue Ge, Tingzhong Tian, Suling Huang, Fangping Wan, Jingxin Li, Shuya Li, et al. (+27)
90 [GO] 2021―Apr―24 Proteome-wide epitope mapping identifies a resource of antibodies for SARS-CoV-2 detection and neutralization Te Liang, Mengli Cheng, Fei Teng, Hongye Wang, Yongqiang Deng, Jiahui Zhang, et al. (+4)
91 [GO] 2021―Apr―24 Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2 Lihong Huang, Terrence Tsz-Tai Yuen, Zuodong Ye, Shuyan Liu, Guoliang Zhang, Hin Chu, Jianbo Yue
92 [GO] 2021―Apr―24 RNA-induced liquid phase separation of SARS-CoV-2 nucleocapsid protein facilitates NF-κB hyper-activation and inflammation Yaoxing Wu, Ling Ma, Sihui Cai, Zhen Zhuang, Zhiyao Zhao, Shouheng Jin, et al. (+5)
93 [GO] 2021―Apr―24 The olfactory route is a potential way for SARS-CoV-2 to invade the central nervous system of rhesus monkeys Li Jiao, Yun Yang, Wenhai Yu, Yuan Zhao, Haiting Long, Jiahong Gao, et al. (+19)
94 [GO] 2021―Apr―24 Adapt or perish: SARS-CoV-2 antibody escape variants defined by deletions in the Spike N-terminal Domain Marta Ribes, Carlos Chaccour, Gemma Moncunill
95 [GO] 2021―Apr―19 Correction to: Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals Fan Zhang, Rui Gan, Ziqi Zhen, Xiaoli Hu, Xiang Li, Fengxia Zhou, et al. (+6)
96 [GO] 2021―Apr―16 COVID-19: complexity of disease severity revealed by systemic and localized single cell immune atlas Nehad M. Alajez
97 [GO] 2021―Apr―15 Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery Yuming Li, Guixue Hou, Haibo Zhou, Yanqun Wang, Hein Min Tun, Airu Zhu, et al. (+25)
98 [GO] 2021―Apr―10 SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency Maochen Li, Fuxing Lou, Huahao Fan
99 [GO] 2021―Apr―09 FcγRIIb blockage: a promising immunotherapy target for severe COVID-19 Xuemei He, Manni Wang, Min Wu
100 [GO] 2021―Apr―09 Landscapes of SARS-CoV-2-reactive CD8+ T cells: heterogeneity of host immune responses against SARS-CoV-2 June-Young Koh, Eui-Cheol Shin
101 [GO] 2021―Apr―01 Antimicrobial peptide DP7 with potential activity against SARS coronavirus infections Rui Zhang, Xiaohua Jiang, Jingxin Qiao, Zeng Wang, Aiping Tong, Jinliang Yang, et al. (+2)
102 [GO] 2021―Mar―31 Longitudinal dynamics of antibody responses in recovered COVID-19 patients Meng-Li Cheng, Hui-Ying Liu, Hui Zhao, Guo-Qing Wang, Chao Zhou, Jing Zheng, et al. (+4)
103 [GO] 2021―Mar―31 Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster Lunzhi Yuan, Huachen Zhu, Ming Zhou, Jian Ma, Rirong Chen, Yao Chen, et al. (+19)
104 [GO] 2021―Mar―27 Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development Miao-Miao Zhao, Wei-Li Yang, Fang-Yuan Yang, Li Zhang, Wei-Jin Huang, Wei Hou, et al. (+5)
105 [GO] 2021―Mar―23 The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2 Cheng Li, Xiaolong Tian, Xiaodong Jia, Jinkai Wan, Lu Lu, Shibo Jiang, et al. (+4)
106 [GO] 2021―Mar―23 Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products Chang-Long He, Lu-Yi Huang, Kai Wang, Chen-Jian Gu, Jie Hu, Gui-Ji Zhang, et al. (+4)
107 [GO] 2021―Mar―15 Unique and complementary suppression of cGAS-STING and RNA sensing- triggered innate immune responses by SARS-CoV-2 proteins Yajuan Rui, Jiaming Su, Si Shen, Ying Hu, Dingbo Huang, Wenwen Zheng, et al. (+10)
108 [GO] 2021―Mar―11 SARS-CoV-2 non-structural protein 13 (nsp13) hijacks host deubiquitinase USP13 and counteracts host antiviral immune response Guijie Guo, Ming Gao, Xiaochen Gao, Bibo Zhu, Jinzhou Huang, Kuntian Luo, et al. (+4)
109 [GO] 2021―Mar―08 COVID-19 in early 2021: current status and looking forward Chengdi Wang, Zhoufeng Wang, Guangyu Wang, Johnson Yiu-Nam Lau, Kang Zhang, Weimin Li
110 [GO] 2021―Mar―08 The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity Leiqiong Gao, Jing Zhou, Sen Yang, Lisha Wang, Xiangyu Chen, Yang Yang, et al. (+11)
111 [GO] 2021―Mar―06 Targeting glucose metabolism for treatment of COVID-19 Amin Ardestani, Zahra Azizi
112 [GO] 2021―Mar―06 Dynamic blood single-cell immune responses in patients with COVID-19 Lulin Huang, Yi Shi, Bo Gong, Li Jiang, Zhixin Zhang, Xiaoqi Liu, et al. (+15)
113 [GO] 2021―Mar―02 Study on the promotion of lymphocytes in patients with COVID-19 by broad-spectrum chemokine receptor inhibitor vMIP-II and its Mechanism of signal transmission in vitro Shiyu Li, Shuting Liu, Zhenyou Jiang, Lixia Feng, Yong Gao, Youyu Chen, et al. (+4)
114 [GO] 2021―Mar―02 ‘nAb’ the self-reactive activity in the COVID-19 combat Madhusudhanan Narasimhan, Lenin Mahimainathan, Alagarraju Muthukumar
115 [GO] 2021―Mar―02 Prognostic value of lymphocyte count in severe COVID-19 patients with corticosteroid treatment Chenyang Lu, Yi Liu, Bo Chen, Hang Yang, Huifang Hu, Yi Liu, Yi Zhao
116 [GO] 2021―Mar―01 TMPRSS2 activity may mediate sex differences in COVID-19 severity Derick Okwan-Duodu, Eun-Cheon Lim, Sungyong You, David M. Engman
117 [GO] 2021―Mar―01 COVID-19: cross-immunity of viral epitopes may influence severity of infection and immune response Junaid Kashir, Khaled AlKattan, Ahmed Yaqinuddin
118 [GO] 2021―Mar―01 D614G and SARS-CoV-2 replication fitness Kathleen D. Engelman, Alan N. Engelman
119 [GO] 2021―Mar―01 Mutation D614G increases SARS-CoV-2 transmission Prerna Arora, Stefan Pöhlmann, Markus Hoffmann
120 [GO] 2021―Feb―26 Auto-antibodies against type I IFNs are associated with severe COVID-19 pneumonia Weilin Zhou, Wei Wang
121 [GO] 2021―Feb―26 SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies Yang Yang, Lanying Du
122 [GO] 2021―Feb―22 Genome and epigenome editing identify CCR9 and SLC6A20 as target genes at the 3p21.31 locus associated with severe COVID-19 Yao Yao, Fei Ye, Kailong Li, Peng Xu, Wenjie Tan, Quansheng Feng, Shuquan Rao
123 [GO] 2021―Feb―22 Therapeutic potential of C1632 by inhibition of SARS-CoV-2 replication and viral-induced inflammation through upregulating let-7 Chen Xie, Yanlian Chen, Dongling Luo, Zhen Zhuang, Heping Jin, Haoxian Zhou, et al. (+8)
124 [GO] 2021―Feb―21 Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials Shaolei Ma, Changsheng Xu, Shijiang Liu, Xiaodi Sun, Renqi Li, Mingjie Mao, et al. (+2)
125 [GO] 2021―Feb―10 Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial Lei Shi, Hai Huang, Xuechun Lu, Xiaoyan Yan, Xiaojing Jiang, Ruonan Xu, et al. (+27)
126 [GO] 2021―Feb―04 Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir Yu Bai, Fei Ye, Yong Feng, Hanyi Liao, Hao Song, Jianxun Qi, et al. (+4)
127 [GO] 2021―Jan―29 Constrained surfaces: promising therapeutic targets for COVID-19 determined by systematically mutational analysis Manni Wang, Tianxia Lan, Wei Wang
128 [GO] 2021―Jan―29 Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA Weihong Zeng, Huan Ma, Chengchao Ding, Yunru Yang, Yong Sun, Xiaoxue Huang, et al. (+4)
129 [GO] 2021―Jan―29 Engaging the spikes: heparan sulfate facilitates SARS-CoV-2 spike protein binding to ACE2 and potentiates viral infection Rajkumar Singh Kalra, Ramesh Kandimalla
130 [GO] 2021―Jan―18 Not only ACE2-the quest for additional host cell mediators of SARS-CoV-2 infection: Neuropilin-1 (NRP1) as a novel SARS-CoV-2 host cell entry mediator implicated in COVID-19 Ioannis Kyrou, Harpal S. Randeva, Demetrios A. Spandidos, Emmanouil Karteris
131 [GO] 2021―Jan―11 Connections between biomechanics and higher infectivity: a tale of the D614G mutation in the SARS-CoV-2 spike protein Anshumali Mittal, Vikash Verma
132 [GO] 2021―Jan―08 Pathological features of COVID-19-associated liver injury-a preliminary proteomics report based on clinical samples Ling Leng, Ruiyuan Cao, Jie Ma, Luye Lv, Wei Li, Yunping Zhu, et al. (+4)
133 [GO] 2021―Jan―01 A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome Weiqi Hong, Jingyun Yang, Zhenfei Bi, Cai He, Hong Lei, Wenhai Yu, et al. (+5)
134 [GO] 2020―Dec―28 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling Yi Zheng, Meng-Wei Zhuang, Lulu Han, Jing Zhang, Mei-Ling Nan, Peng Zhan, et al. (+4)
135 [GO] 2020―Dec―24 Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19 Hong-Yi Zheng, Min Xu, Cui-Xian Yang, Ren-Rong Tian, Mi Zhang, Jian-Jian Li, et al. (+8)
136 [GO] 2020―Dec―24 Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches Yuefei Jin, Wangquan Ji, Haiyan Yang, Shuaiyin Chen, Weiguo Zhang, Guangcai Duan
137 [GO] 2020―Dec―14 Scoring cytokine storm by the levels of MCP-3 and IL-8 accurately distinguished COVID-19 patients with high mortality Liting Chen, Gaoxiang Wang, Jiaqi Tan, Yang Cao, Xiaolu Long, Hui Luo, et al. (+4)
138 [GO] 2020―Dec―11 Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection Carlos Loucera, Marina Esteban-Medina, Kinza Rian, Matías M. Falco, Joaquín Dopazo, María Peña-Chilet
139 [GO] 2020―Dec―11 Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2 Hong Lei, Aqu Alu, Jingyun Yang, Cai He, Weiqi Hong, Zesheng Cheng, et al. (+6)
140 [GO] 2020―Dec―04 Characteristics of SARS-CoV-2-specific cytotoxic T cells revealed by single-cell immune profiling of longitudinal COVID-19 blood samples Qing Xiong, Cheng Peng, Xiaomin Yan, Xueqi Yan, Lin Chen, Beicheng Sun, Shiping Jiao
141 [GO] 2020―Dec―04 Asynchronous actions of immune responses in COVID-19 patients Yufang Shi, Guoqiang Zhou, Qing Li
142 [GO] 2020―Dec―04 CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells Ke Wang, Wei Chen, Zheng Zhang, Yongqiang Deng, Jian-Qi Lian, Peng Du, et al. (+39)
143 [GO] 2020―Nov―27 RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response Zezhong Liu, Wei Xu, Shuai Xia, Chenjian Gu, Xinling Wang, Qian Wang, et al. (+9)
144 [GO] 2020―Nov―24 Low-dose corticosteroid combined with immunoglobulin reverses deterioration in severe cases with COVID-19 Zhi-Guo Zhou, Di-Xuan Jiang, Shu-Min Xie, Jing Zhang, Fang Zheng, Hong Peng, et al. (+3)
145 [GO] 2020―Nov―24 The effect of whey protein on viral infection and replication of SARS-CoV-2 and pangolin coronavirus in vitro Huahao Fan, Bixia Hong, Yuqian Luo, Qi Peng, Liqin Wang, Xiangshu Jin, et al. (+8)
146 [GO] 2020―Nov―24 Battle at the entrance gate: CIITA as a weapon to prevent the internalization of SARS-CoV-2 and Ebola viruses Rafal Butowt, Krzysztof Pyrc, Christopher S. von Bartheld
147 [GO] 2020―Nov―17 Bimodular effects of D614G mutation on the spike glycoprotein of SARS-CoV-2 enhance protein processing, membrane fusion, and viral infectivity Xiaoyi Jiang, Zhengrong Zhang, Chenxi Wang, Hongguang Ren, Lihua Gao, Haoran Peng, et al. (+4)
148 [GO] 2020―Nov―17 A systemic and molecular study of subcellular localization of SARS-CoV-2 proteins Jing Zhang, Ruth Cruz-cosme, Meng-Wei Zhuang, Dongxiao Liu, Yuan Liu, Shaolei Teng, et al. (+2)
149 [GO] 2020―Nov―17 GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro Kyung Soo Hong, June Hong Ahn, Jong Geol Jang, Jong Ho Lee, Hong Nam Kim, Dongha Kim, Wonhwa Lee
150 [GO] 2020―Nov―13 Baicalein inhibits SARS-CoV-2/VSV replication with interfering mitochondrial oxidative phosphorylation in a mPTP dependent manner Shichao Huang, Yu’e Liu, Yanan Zhang, Ru Zhang, ChengJie Zhu, Lihong Fan, et al. (+3)
151 [GO] 2020―Nov―03 Outsmarting SARS-CoV-2 by empowering a decoy ACE2 Milena Sokolowska
152 [GO] 2020―Nov―02 COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms Peijie Zhong, Jing Xu, Dong Yang, Yue Shen, Lu Wang, Yun Feng, et al. (+5)
153 [GO] 2020―Oct―31 Inflammatory cytokines, T lymphocyte subsets, and ritonavir involved in liver injury of COVID-19 patients Shengtao Liao, Ke Zhan, Li Gan, Yang Bai, Jinfang Li, Guodan Yuan, et al. (+4)
154 [GO] 2020―Oct―30 SARS-CoV-2 spike behavior in situ: a Cryo-EM images for a better understanding of the COVID-19 pandemic Alaa M. Ismail, Abdo A. Elfiky
155 [GO] 2020―Oct―30 SARS-CoV-2 spike protein: flexibility as a new target for fighting infection Ciro Leonardo Pierri
156 [GO] 2020―Oct―23 Omics study reveals abnormal alterations of breastmilk proteins and metabolites in puerperant women with COVID-19 Yin Zhao, You Shang, Yujie Ren, Yuanyuan Bie, Yang Qiu, Yin Yuan, et al. (+4)
157 [GO] 2020―Oct―15 Pathological features of COVID-19-associated lung injury: a preliminary proteomics report based on clinical samples Ling Leng, Ruiyuan Cao, Jie Ma, Danlei Mou, Yunping Zhu, Wei Li, et al. (+14)
158 [GO] 2020―Oct―13 A systematic review of SARS-CoV-2 vaccine candidates Yetian Dong, Tong Dai, Yujun Wei, Long Zhang, Min Zheng, Fangfang Zhou
159 [GO] 2020―Oct―10 Azvudine (FNC): a promising clinical candidate for COVID-19 treatment Bin Yu, Junbiao Chang
160 [GO] 2020―Oct―09 Inhibition of translation and immune responses by the virulence factor Nsp1 of SARS-CoV-2 Kendra R. Vann, Adam H. Tencer, Tatiana G. Kutateladze
161 [GO] 2020―Oct―09 SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation Shufen Li, Yulan Zhang, Zhenqiong Guan, Huiling Li, Meidi Ye, Xi Chen, et al. (+5)
162 [GO] 2020―Oct―06 Is smaller better? Vaccine targeting recombinant receptor-binding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic Manish Muhuri, Guangping Gao
163 [GO] 2020―Oct―06 The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series Hao Zeng, Dongfang Wang, Jingmin Nie, Haoyu Liang, Jiang Gu, Anne Zhao, et al. (+15)
164 [GO] 2020―Oct―06 Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein Chan Yang, Xiaoyan Pan, Xinfeng Xu, Chen Cheng, Yuan Huang, Lin Li, et al. (+4)
165 [GO] 2020―Oct―06 Main protease of SARS-CoV-2 serves as a bifunctional molecule in restricting type I interferon antiviral signaling Yaoxing Wu, Ling Ma, Zhen Zhuang, Sihui Cai, Zhiyao Zhao, Lingli Zhou, et al. (+4)
166 [GO] 2020―Oct―06 SARS-CoV-2-specific T-cells in unexposed humans: presence of cross-reactive memory cells does not equal protective immunity Rory D. de Vries
167 [GO] 2020―Oct―06 SARS-CoV-2: the many pros of targeting PLpro Christopher B. McClain, Nicolas Vabret
168 [GO] 2020―Oct―03 Identification and validation of predictive factors for progression to severe COVID-19 pneumonia by proteomics Biao Di, Hongling Jia, Oscar Junhong Luo, Fangqin Lin, Kuibiao Li, Yuanliang Zhang, et al. (+4)
169 [GO] 2020―Oct―03 A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2 Zhe-Rui Zhang, Ya-Nan Zhang, Xiao-Dan Li, Hong-Qing Zhang, Shu-Qi Xiao, Fei Deng, et al. (+3)
170 [GO] 2020―Sep―22 Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2 Fei Yu, Rong Xiang, Xiaoqian Deng, Lili Wang, Zhengsen Yu, Shijun Tian, et al. (+4)
171 [GO] 2020―Sep―19 Targeting multiple epitopes on the spike protein: a new hope for COVID-19 antibody therapy Yeping Sun, Bostjan Kobe, Jianxun Qi
172 [GO] 2020―Sep―15 Convalescent plasma therapy for COVID-19: a tried-and-true old strategy? Yongzhi Xi
173 [GO] 2020―Sep―14 Type I IFN deficiency: an immunological characteristic of severe COVID-19 patients Zhenling Wang, Hailong Pan, Boguang Jiang
174 [GO] 2020―Sep―07 Storm of soluble immune checkpoints associated with disease severity of COVID-19 Yaxian Kong, Yu Wang, Xueying Wu, Junyan Han, Guoli Li, Mingxi Hua, et al. (+4)
175 [GO] 2020―Sep―03 COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm Wonhwa Lee, June Hong Ahn, Hee Ho Park, Hong Nam Kim, Hyelim Kim, Youngbum Yoo, et al. (+7)
176 [GO] 2020―Sep―03 Profiling and characterization of SARS-CoV-2 mutants’ infectivity and antigenicity Lin Wang, Ling Wang, Hui Zhuang
177 [GO] 2020―Sep―02 Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19 Xiangyu Chen, Zhiwei Pan, Shuai Yue, Fei Yu, Junsong Zhang, Yang Yang, et al. (+16)
178 [GO] 2020―Aug―31 Immune characteristics of severe and critical COVID-19 patients Li Yang, Jianjun Gou, Jianbo Gao, Lan Huang, Zhiqiang Zhu, Shaofei Ji, et al. (+4)
179 [GO] 2020―Aug―27 Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial Fanping Meng, Ruonan Xu, Siyu Wang, Zhe Xu, Chao Zhang, Yuanyuan Li, et al. (+18)
180 [GO] 2020―Aug―25 Molecular features of IGHV3-53-encoded antibodies elicited by SARS-CoV-2 Francesca Fagiani, Michele Catanzaro, Cristina Lanni
181 [GO] 2020―Aug―19 Comparison of nonhuman primates identified the suitable model for COVID-19 Shuaiyao Lu, Yuan Zhao, Wenhai Yu, Yun Yang, Jiahong Gao, Junbin Wang, et al. (+28)
182 [GO] 2020―Aug―14 Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals Fan Zhang, Rui Gan, Ziqi Zhen, Xiaoli Hu, Xiang Li, Fengxia Zhou, et al. (+6)
183 [GO] 2020―Jul―29 Crystal structure of SARS-CoV-2 nsp10/nsp16 2′-O-methylase and its implication on antiviral drug design Sheng Lin, Hua Chen, Fei Ye, Zimin Chen, Fanli Yang, Yue Zheng, et al. (+4)
184 [GO] 2020―Jul―25 COVID-19: immunopathogenesis and Immunotherapeutics Li Yang, Shasha Liu, Jinyan Liu, Zhixin Zhang, Xiaochun Wan, Bo Huang, et al. (+2)
185 [GO] 2020―Jul―08 Single cell transcriptome revealed SARS-CoV-2 entry genes enriched in colon tissues and associated with coronavirus infection and cytokine production Haoyan Chen, Tian-Hui Zou, Baoqin Xuan, Yuqing Yan, Tingting Yan, Chaoqin Shen, et al. (+5)
186 [GO] 2020―Jul―02 Mapping the T cell response to COVID-19 Junwei Li, Junhua Wang, Angray S. Kang, Pradeep Kumar Sacitharan
187 [GO] 2020―Jun―26 Door to the cell for COVID-19 opened, leading way to therapies Zhiwei Huang, Jijie Chai
188 [GO] 2020―Jun―19 Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients Zhi-Sheng Xu, Ting Shu, Liang Kang, Di Wu, Xing Zhou, Bo-Wei Liao, et al. (+3)
189 [GO] 2020―Jun―17 Targeting the entry step of SARS-CoV-2: a promising therapeutic approach Jing Li, Peng Zhan, Xinyong Liu
190 [GO] 2020―Jun―12 Overview of lethal human coronaviruses Bin Chen, Er-Kang Tian, Bin He, Lejin Tian, Ruiying Han, Shuangwen Wang, et al. (+4)
191 [GO] 2020―Jun―12 The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin Shuai Xia, Qiaoshuai Lan, Shan Su, Xinling Wang, Wei Xu, Zezhong Liu, et al. (+4)
192 [GO] 2020―May―29 Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2 Michele Catanzaro, Francesca Fagiani, Marco Racchi, Emanuela Corsini, Stefano Govoni, Cristina Lanni
193 [GO] 2020―May―21 A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2 Shan Su, Shibo Jiang
194 [GO] 2020―May―09 Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease Mpro Hylemariam Mihiretie Mengist, Xiaojiao Fan, Tengchuan Jin
195 [GO] 2020―May―08 Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo Wei Deng, Yanfeng Xu, Qi Kong, Jing Xue, Pin Yu, Jiangning Liu, et al. (+4)
196 [GO] 2020―May―05 Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study Dongze Li, You Chen, Hong Liu, Yu Jia, Fanghui Li, Wei Wang, et al. (+4)
197 [GO] 2020―Apr―29 Correction: Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study Li Tan, Qi Wang, Duanyang Zhang, Jinya Ding, Qianchuan Huang, Yi-Quan Tang, et al. (+2)
198 [GO] 2020―Apr―28 A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia Yin Wang, Weiwei Jiang, Qi He, Cheng Wang, Baoju Wang, Pan Zhou, et al. (+2)
199 [GO] 2020―Mar―27 Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study Li Tan, Qi Wang, Duanyang Zhang, Jinya Ding, Qianchuan Huang, Yi-Quan Tang, et al. (+2)
200 [GO] 2020―Feb―21 Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia Wei Zhou, Yisi Liu, Dongdong Tian, Cheng Wang, Sa Wang, Jing Cheng, et al. (+3)


[de][en]

Last change 2022―Jan―20 20:43:25 UTC

© Daten-Quadrat 2022       Done in 0.005 sec